2023
DOI: 10.1007/s11864-023-01054-7
|View full text |Cite
|
Sign up to set email alerts
|

A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 62 publications
0
1
0
1
Order By: Relevance
“…Soft tissue sarcomas (STS) are rare malignant tumours arising from mesenchymal tissues which make up around 2% of all adult malignancies [ 1 ]. Undifferentiated pleomorphic sarcoma (UPS), formerly known as malignant fibrous histiocytoma (MFH) or high-grade spindle cell sarcoma, is an aggressive form of soft tissue sarcoma which makes up 10–20% of STS [ 2 ]. It is commoner in males and frequently presents as a soft tissue tumour in the thigh and wall of the trunk.…”
Section: Introductionmentioning
confidence: 99%
“…Soft tissue sarcomas (STS) are rare malignant tumours arising from mesenchymal tissues which make up around 2% of all adult malignancies [ 1 ]. Undifferentiated pleomorphic sarcoma (UPS), formerly known as malignant fibrous histiocytoma (MFH) or high-grade spindle cell sarcoma, is an aggressive form of soft tissue sarcoma which makes up 10–20% of STS [ 2 ]. It is commoner in males and frequently presents as a soft tissue tumour in the thigh and wall of the trunk.…”
Section: Introductionmentioning
confidence: 99%
“…Por ejemplo, la trabectedina y el pazopanib demuestran actividad en varios subtipos de sarcomas de partes blandas, pero su estudio en pacientes con sarcoma pleomórfico indiferenciado es más limitado. El sarcoma pleomórfico indiferenciado tiene unas características que lo diferencian del resto de sarcomas de partes blandas, incluyendo una mayor expresión de PD-1/PD-L1, una mayor infiltración de células T, una mayor presentación de antígenos y una mayor carga tumoral mutacional (TMB); por ello los ensayos clínicos deberían centrarse en lo que lo hace diferente respecto a los otros sarcomas en lugar de extrapolar los resultados de otros sarcomas de partes blandas a todos los subtipos 240 .…”
Section: Algunos Autores Han Creado Protocolos Terapéuticos En Funció...unclassified